Abstract: The present invention relates to a method for preventing transmission of influenza, wherein said method comprises administering an effective amount of a compound to a patient having an influenza virus infection, herein referred to as “index patient”, wherein the compound has one of the formulae (I) and (II), or its pharmaceutically acceptable salt. The compound to be used in the present invention reduces infectivity of the influenza virus of the index patient, and therefore, reduces the risk of the index patient to trigger an influenza epidemic or an influenza pandemic as compared to a control patient.

Abstract: A method for treating influenza is described. The disclosed method generally involves administering an effective amount of a compound, for example baloxavir marboxil, to a subject having influenza, where the compound is administered initially at least about 48 hours after an onset of influenza. Generally, the effective amount is sufficient to alleviate a symptom of influenza in the subject as compared to a symptom that the subject has when the compound is first administered to the subject.

Abstract: A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.

Abstract: The present invention relates to a method for preventing transmission of influenza, wherein said method comprises administering an effective amount of a compound to a patient having an influenza virus infection, herein referred to as “index patient”, wherein the compound has one of the formulae (I) and (II), or its pharmaceutically acceptable salt. The compound to be used in the present invention reduces infectivity of the influenza virus of the index patient, and therefore, reduces the risk of the index patient to trigger an influenza epidemic or an influenza pandemic as compared to a control patient.

Abstract: The present invention relates to a method for preventing transmission of influenza, wherein said method comprises administering an effective amount of a compound to a patient having an influenza virus infection, herein referred to as “index patient”, wherein the compound has one of the formulae (I) and (II), or its pharmaceutically acceptable salt. The compound to be used in the present invention reduces infectivity of the influenza virus of the index patient, and therefore, reduces the risk of the index patient to trigger an influenza epidemic or an influenza pandemic as compared to a control patient.

Abstract: A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.

Abstract: A method for treating influenza is described. The disclosed method generally involves administering an effective amount of a compound, for example baloxavir marboxil, to a subject having influenza, where the compound is administered initially at least about 48 hours after an onset of influenza. Generally, the effective amount is sufficient to alleviate a symptom of influenza in the subject as compared to a symptom that the subject has when the compound is first administered to the subject.

Abstract: A medicament characterized in that (A) a compound represented by the formula (I): its pharmaceutically acceptable salt, or a solvate thereof, wherein P is hydrogen or a group to form a prodrug; A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is each independently CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A4 is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A are each independently hydrogen, halogen, alkyl, or the like; R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together with an adjacent carbon atom to form non-aromatic carbocycle or non-aromatic heterocycle; n is any integer of 1 to 2; and R1 is or the like, is combined

Abstract: The present invention relates to a method for preventing transmission of influenza, wherein said method comprises administering an effective amount of a compound to a patient having an influenza virus infection, herein referred to as “index patient”, wherein the compound has one of the formulae (I) and (II), or its pharmaceutically acceptable salt. The compound to be used in the present invention reduces infectivity of the influenza virus of the index patient, and therefore, reduces the risk of the index patient to trigger an influenza epidemic or an influenza pandemic as compared to a control patient.

Abstract: A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.

Abstract: A medicament characterized in that (A) a compound represented by the formula (I): its pharmaceutically acceptable salt, or a solvate thereof, wherein P is hydrogen or a group to form a prodrug; A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is each independently CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A4 is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A are each independently hydrogen, halogen, alkyl, or the like; R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together with an adjacent carbon atom to form non-aromatic carbocycle or non-aromatic heterocycle; n is any integer of 1 to 2; and R1 is or the like,

Abstract: An organic electroluminescent element including a substrate, a first electrode, a partition wall next to the first electrode, an organic luminescent medium layer including an organic luminescent layer on the first electrode and second electrode is provided. The organic luminescent medium layer can be between the first electrode and the second electrode. An area where the organic luminescent medium layer is between the first electrode and the second electrode is a light emitting area. At least one layer among the organic luminescent medium layer is continuously formed from the light emitting area to a top face of the partition wall.

Abstract: A screening method for a compound which inhibits a ribonuclease H activity of a reverse transcriptase which includes incubating a substrate with an appropriate primer hybridized to an appropriate template, a metal ion and a reverse transcriptase to form a complex, adding a test substance, and after these steps adding dNTPs to initiate DNA synthesis, measuring the amount of nucleic acid cleaved from the template, and comparing the measured value with a measured value in the absence of a test substance.

Abstract: By using Template: 5?-NRWXZ-3? Primer: 3?-Y-5? (wherein, Y hybridizes to X of a template, N is 13-19 mer DNA, RNA or a chimeric nucleic acid, R is RNA, W is DNA or a chimeric nucleic acid, X is 15 mer or more DNA, RNA or a chimeric nucleic acid, Y is a same length DNA, RNA or a chimeric nucleic acid with X to which Y hybridizes. In case that X to which Y hybridizes is DNA, Y is DNA. In case that X to which Y hybridizes is RNA, Y is RNA. In case that X to which Y hybridizes is a chimeric nucleic acid, Y is a chimeric nucleic acid (In the chimeric nucleic acid, in case that X to which Y hybridizes is DNA, Y is DNA. In case that X to which Y hybridizes is RNA, Y is RNA), Z is DNA, RNA or a chimeric nucleic acid (provided that, W and Z can be absent)), a test compound can be preincubated with a reverse transcriptase-substrate complex formed under the presence of a metal ion and a screening method for a substance which inhibits polymerization-dependent RNase H activity is established.

Abstract: A manufacturing method of a display device is disclosed. The display device can include: partition walls, a displaying part sectioned by the partition walls, a display function layer within the displaying part, and a substrate holding the partition walls, and the display function layer. The method can comprise forming at least one layer of the display function layer by an ink droplet supplied by transposition from an ink feed body, wherein the ink droplet is separated from the ink feed body after the ink droplet touches a region sectioned by the partition walls. After ink touched a region sectioned by partition walls, ink separates from ink feed body. Transposition of ink droplet forming the display layer is performed in this way. Therefore, even if a partition wall is not high, a partition wall can prevent ink droplet from scattering to other sections. Therefore, even if a partition wall does not include ink-repellent agent, a partition wall can prevent ink droplet from scattering to other sections.

Abstract: An organic electroluminescent element including a substrate, a first electrode, a partition wall next to the first electrode, an organic luminescent medium layer including an organic luminescent layer on the first electrode and second electrode is provided. The organic luminescent medium layer can be between the first electrode and the second electrode. An area where the organic luminescent medium layer is between the first electrode and the second electrode is a light emitting area. At least one layer among the organic luminescent medium layer is continuously formed from the light emitting area to a top face of the partition wall.